Hemagglutinin polypeptides, and reagents and methods relating thereto
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/145
C12N-007/00
A61K-039/12
출원번호
US-0253060
(2011-10-04)
등록번호
US-10226527
(2019-03-12)
발명자
/ 주소
Tharakaraman, Kannan
Viswanathan, Karthik
Raman, Rahul
Sasisekharan, Ram
출원인 / 주소
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
대리인 / 주소
Choate, Hall & Stewart LLP
인용정보
피인용 횟수 :
0인용 특허 :
34
초록
The present invention provides a system for analyzing interactions between glycans and interaction partners that bind to them. The present invention also provides HA polypeptides that bind to umbrella-topology glycans, and reagents and methods relating thereto.
대표청구항▼
1. A pharmaceutical composition comprising: a polypeptide that is a H5 hemagglutinin (“HA”) polypeptide having an amino acid sequence, using positions based on the canonical H3 numbering system that: i) differs from but shows at least 95% identity with that of a reference H5 HA selected from the gro
1. A pharmaceutical composition comprising: a polypeptide that is a H5 hemagglutinin (“HA”) polypeptide having an amino acid sequence, using positions based on the canonical H3 numbering system that: i) differs from but shows at least 95% identity with that of a reference H5 HA selected from the group consisting of A/Vietnam/1203/04 (SEQ ID NO: 50), A/Egypt/2786-NAMRU3/06 (SEQ ID NO: 51), and A/chicken/Vietnam/NCVD-093/08 (SEQ ID NO: 69);ii) has a deletion at one or more positions selected from the group consisting of: 128, 129, 130, 131, 132, 133, 134, 135, 136, and combinations thereof; and, except for the deletion,iii) maintains conserved residues of HA Sequence Elements 1 and 2 as set forth in SEQ ID NO: 106 and SEQ ID NO: 118, respectively. 2. The pharmaceutical composition of claim 1, wherein the H5 HA polypeptide competes with the reference H5 HA polypeptide for interaction with an umbrella topology glycan. 3. The pharmaceutical composition of claim 1, wherein the H5 HA polypeptide amino acid sequence has a deletion of the amino acid residue at a position selected from 130, 131, 132, and 133. 4. The pharmaceutical composition of claim 2, wherein the umbrella topology glycan comprises long α2-6 sialylated glycans. 5. The pharmaceutical composition of claim 4, wherein the long α2-6 sialylated glycans are selected from the group consisting of Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAc, Neu5Acα2-6GalNAcβ1-4GlcNAcβ1-3 GalNAcβ1-4GlcNAc, Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GalNAc, Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-3GalNAc, Neu5Acα2-6GalNAcβ1-4GlcNAcβ1-3Galβ1-4GalNAc, Neu5Acα2-6GalNAcβ1-4GlcNAcβ1-3 GalNAcβ1-4GlcNAcβ1-3Galβ1-3GalNAc, NeuAcα2-3Galβ1-3 GalNAcα2-6Neu5Ac, Neu5Acα2-6Galβ1-4GlcNAcβ1-3/6GalNAc, Neu5Acα2-6Galβ1-4GlcNAcβ1-3 Galβ1-4GlcNAcβ1-3/6GalNAc, Neu5Acα2-6GalNAcβ1-4GlcNAcβ1-3/6GalNAc, Neu5Acα2-6GalNAcβ1-4GlcNAcβ1-3GalNAcβ1-4GlcNAcβ1-3/6GalNAc, NeuAcα2-6Galβ1-4GalNAcβ1-6GlcNAcβ1-3 Galα2-3Neu5Ac, NeuAcα2-6Galβ1-4GalNAcβ1-3/6GlcNAcβ1-3/6Galα2-3/6Neu5Ac, Neu5Acα2-6Galβ1-3GalNAcβ1-4Galα1-3Galβ1-4Glc, Neu5Acα2-6Galβ1-3GalNAcβ1-3Galβ1-4Galβ1-4Glc, Neu5Acα2-6Galβ1-3GlcNAcβ1-3Galβ1-4Glc and Neu5Acα2-6Galβ1-4GlcNAcβ1-3 Galβ1-4Glc. 6. The pharmaceutical composition of claim 2, wherein the H5 HA polypeptide binds to umbrella topology glycans with an affinity that is at least 50%, at least 70%, at B least 80%, at least 90% or at least 100% of that observed for a wild type HA that mediates infection of humans. 7. The pharmaceutical composition of claim 2, wherein the H5 HA polypeptide binds to umbrella topology glycans with greater affinity than it binds to cone topology glycans. 8. The pharmaceutical composition of claim 2, wherein the H5 HA polypeptide shows a relative affinity for umbrella topology glycans versus cone topology glycans of at least 2. 9. The pharmaceutical composition of claim 2, wherein the H5 HA polypeptide shows a relative affinity for umbrella topology glycans versus cone topology glycans of at least 5. 10. The pharmaceutical composition of claim 2, wherein the H5 HA polypeptide shows a relative affinity for umbrella topology glycans versus cone topology glycans of at least 10. 11. The pharmaceutical composition of claim 2, wherein the interaction occurs between the H5 HA polypeptide and umbrella topology glycans on HA receptors found on human upper respiratory epithelial cells, the bronchus, trachea, or the deep lung. 12. The pharmaceutical composition of claim 1, wherein the H5 HA polypeptide differs from the reference H5 HA polypeptide at one or more positions selected from the group consisting of 131, 132, 133, 137, 155, 159, 160, 193, 224, and 226.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (34)
Peterson Steven F. (West Linn OR), Ampule filling device.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.